Associations - PD-L1 overexpression

PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials SITC 2021 - 3 weeks	Immunotherapy Sensitive: C3 – Early Trials SITC 2021 - 3 weeks
PD-L1 overexpression PD-L1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	PD-L1 overexpression PD-L1 overexpression	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	avelumab + binimetinib Sensitive: C3 – Early Trials SITC 2021 - 3 weeks	avelumab + binimetinib Sensitive: C3 – Early Trials SITC 2021 - 3 weeks
PD-L1 overexpression PD-L1 overexpression	Mesothelioma Mesothelioma	PD-L1 overexpression PD-L1 overexpression	Mesothelioma Mesothelioma	pembrolizumab + nintedanib Sensitive: C3 – Early Trials SITC 2021 - 3 weeks	pembrolizumab + nintedanib Sensitive: C3 – Early Trials SITC 2021 - 3 weeks
PD-L1 overexpression PD-L1 overexpression	Hepatocellular Cancer HCC	PD-L1 overexpression PD-L1 overexpression	Hepatocellular Cancer HCC	durvalumab + cabozantinib tablet Sensitive: C3 – Early Trials SITC 2021 - 3 weeks	durvalumab + cabozantinib tablet Sensitive: C3 – Early Trials SITC 2021 - 3 weeks
PD-L1 overexpression PD-L1 overexpression	Colorectal Cancer CRC	PD-L1 overexpression PD-L1 overexpression	Colorectal Cancer CRC	durvalumab + cabozantinib tablet Sensitive: C3 – Early Trials SITC 2021 - 3 weeks	durvalumab + cabozantinib tablet Sensitive: C3 – Early Trials SITC 2021 - 3 weeks
PD-L1 overexpression PD-L1 overexpression	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	PD-L1 overexpression PD-L1 overexpression	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	durvalumab + cabozantinib tablet Sensitive: C3 – Early Trials SITC 2021 - 3 weeks	durvalumab + cabozantinib tablet Sensitive: C3 – Early Trials SITC 2021 - 3 weeks
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	cemiplimab Sensitive: A1 - Approval Sanofi Press Release - 4 weeks	cemiplimab Sensitive: A1 - Approval Sanofi Press Release - 4 weeks
PD-L1 overexpression PD-L1 overexpression	Oral Cancer Oral Cancer	PD-L1 overexpression PD-L1 overexpression	Oral Cancer Oral Cancer	pembrolizumab Sensitive: C4 – Case Studies Oral Oncol - 4 weeks	pembrolizumab Sensitive: C4 – Case Studies Oral Oncol - 4 weeks
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval	atezolizumab Sensitive: A1 - Approval
PD-L1 overexpression PD-L1 overexpression	Urothelial Cancer Urothelial Cancer	PD-L1 overexpression PD-L1 overexpression	Urothelial Cancer Urothelial Cancer	tislelizumab Sensitive: A1 - Approval	tislelizumab Sensitive: A1 - Approval
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
PD-L1 overexpression PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 overexpression PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	bevacizumab + atezolizumab Sensitive: A2 - Guideline	bevacizumab + atezolizumab Sensitive: A2 - Guideline
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	bevacizumab Sensitive: A2 - Guideline	bevacizumab Sensitive: A2 - Guideline
PD-L1 overexpression PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	PD-L1 overexpression PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	atezolizumab Sensitive: A2 - Guideline	atezolizumab Sensitive: A2 - Guideline
PD-L1 overexpression PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	PD-L1 overexpression PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
PD-L1 overexpression PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	PD-L1 overexpression PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline	nivolumab + ipilimumab Sensitive: A2 - Guideline
PD-L1 overexpression PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	PD-L1 overexpression PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	cemiplimab Sensitive: A2 - Guideline	cemiplimab Sensitive: A2 - Guideline
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	atezolizumab + MTIG7192A Sensitive: B - Late Trials	atezolizumab + MTIG7192A Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	carboplatin + albumin-bound paclitaxel Sensitive: B - Late Trials	carboplatin + albumin-bound paclitaxel Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	carboplatin + gemcitabine Sensitive: B - Late Trials	carboplatin + gemcitabine Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	cisplatin + albumin-bound paclitaxel Sensitive: B - Late Trials	cisplatin + albumin-bound paclitaxel Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	GC Sensitive: B - Late Trials	GC Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	carboplatin + pemetrexed Sensitive: B - Late Trials	carboplatin + pemetrexed Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	cisplatin + pemetrexed Sensitive: B - Late Trials	cisplatin + pemetrexed Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	GastroEsophageal Cancer GastroEsophageal Cancer	PD-L1 overexpression PD-L1 overexpression	GastroEsophageal Cancer GastroEsophageal Cancer	PD1 inhibitor Sensitive: B - Late Trials	PD1 inhibitor Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	GastroEsophageal Cancer GastroEsophageal Cancer	PD-L1 overexpression PD-L1 overexpression	GastroEsophageal Cancer GastroEsophageal Cancer	PD-L1 inhibitor Sensitive: B - Late Trials	PD-L1 inhibitor Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	PD-L1 overexpression PD-L1 overexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	pembrolizumab Sensitive: B - Late Trials	pembrolizumab Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	tislelizumab Sensitive: B - Late Trials	tislelizumab Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Urothelial Cancer Urothelial Cancer	PD-L1 overexpression PD-L1 overexpression	Urothelial Cancer Urothelial Cancer	durvalumab Sensitive: B - Late Trials	durvalumab Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	nivolumab Sensitive: B - Late Trials	nivolumab Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	avelumab Sensitive: B - Late Trials	avelumab Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab Sensitive: B - Late Trials	durvalumab Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	PD-L1 overexpression PD-L1 overexpression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	pembrolizumab Sensitive: B - Late Trials	pembrolizumab Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Gastric Cancer Gastric Cancer	PD-L1 overexpression PD-L1 overexpression	Gastric Cancer Gastric Cancer	pembrolizumab Sensitive: B - Late Trials	pembrolizumab Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	PD-L1 overexpression PD-L1 overexpression	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: B - Late Trials	pembrolizumab Sensitive: B - Late Trials
PD-L1 overexpression PD-L1 overexpression	Ovarian Cancer Ovarian Cancer	PD-L1 overexpression PD-L1 overexpression	Ovarian Cancer Ovarian Cancer	atezolizumab Sensitive: C1 - Off-label	atezolizumab Sensitive: C1 - Off-label
PD-L1 overexpression PD-L1 overexpression	Urothelial Cancer Urothelial Cancer	PD-L1 overexpression PD-L1 overexpression	Urothelial Cancer Urothelial Cancer	PF-06801591 Sensitive: C2 – Inclusion Criteria	PF-06801591 Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression PD-L1 overexpression	Sarcoma Sarcoma	PD-L1 overexpression PD-L1 overexpression	Sarcoma Sarcoma	nivolumab + ipilimumab Sensitive: C2 – Inclusion Criteria	nivolumab + ipilimumab Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	durvalumab Sensitive: C2 – Inclusion Criteria	durvalumab Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	pembrolizumab + niraparib Sensitive: C2 – Inclusion Criteria	pembrolizumab + niraparib Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: C2 – Inclusion Criteria	pembrolizumab Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression PD-L1 overexpression	Lung Adenocarcinoma LUAD	PD-L1 overexpression PD-L1 overexpression	Lung Adenocarcinoma LUAD	pembrolizumab Sensitive: C2 – Inclusion Criteria	pembrolizumab Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	INCMGA0012 Sensitive: C2 – Inclusion Criteria	INCMGA0012 Sensitive: C2 – Inclusion Criteria
PD-L1 overexpression PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 overexpression PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	camrelizumab Sensitive: C3 – Early Trials	camrelizumab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	PD-L1 overexpression PD-L1 overexpression	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	GB226 Sensitive: C3 – Early Trials	GB226 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	PD-L1 overexpression PD-L1 overexpression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	nivolumab + ibrutinib Sensitive: C3 – Early Trials	nivolumab + ibrutinib Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	durvalumab + CP-675206 Sensitive: C3 – Early Trials	durvalumab + CP-675206 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Prostate Cancer Prostate Cancer	PD-L1 overexpression PD-L1 overexpression	Prostate Cancer Prostate Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials	PD-L1 inhibitor Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Gastric Cancer Gastric Cancer	PD-L1 overexpression PD-L1 overexpression	Gastric Cancer Gastric Cancer	trastuzumab Sensitive: C3 – Early Trials	trastuzumab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non-Hodgkin’s Lymphoma NHL	PD-L1 overexpression PD-L1 overexpression	Non-Hodgkin’s Lymphoma NHL	avelumab Sensitive: C3 – Early Trials	avelumab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	PD-L1 overexpression PD-L1 overexpression	Triple Negative Breast Cancer Triple Negative Breast Cancer	olaparib Sensitive: C3 – Early Trials	olaparib Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Solid Tumor Solid Tumor	PD-L1 overexpression PD-L1 overexpression	Solid Tumor Solid Tumor	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non-Hodgkin’s Lymphoma NHL	PD-L1 overexpression PD-L1 overexpression	Non-Hodgkin’s Lymphoma NHL	AB122 Sensitive: C3 – Early Trials	AB122 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	PD-L1 overexpression PD-L1 overexpression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	MGD013 Sensitive: C3 – Early Trials	MGD013 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Bladder Cancer Bladder Cancer	PD-L1 overexpression PD-L1 overexpression	Bladder Cancer Bladder Cancer	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Lung Adenocarcinoma LUAD	PD-L1 overexpression PD-L1 overexpression	Lung Adenocarcinoma LUAD	pemetrexed Sensitive: C3 – Early Trials	pemetrexed Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	PD-L1 overexpression PD-L1 overexpression	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	PD-L1 overexpression PD-L1 overexpression	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Solid Tumor Solid Tumor	PD-L1 overexpression PD-L1 overexpression	Solid Tumor Solid Tumor	avelumab + IMP 321 Sensitive: C3 – Early Trials	avelumab + IMP 321 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Solid Tumor Solid Tumor	PD-L1 overexpression PD-L1 overexpression	Solid Tumor Solid Tumor	IMP 321 Sensitive: C3 – Early Trials	IMP 321 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PF-06801591 Sensitive: C3 – Early Trials	PF-06801591 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Melanoma Melanoma	PD-L1 overexpression PD-L1 overexpression	Melanoma Melanoma	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Gastric Cancer Gastric Cancer	PD-L1 overexpression PD-L1 overexpression	Gastric Cancer Gastric Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Bladder Cancer Bladder Cancer	PD-L1 overexpression PD-L1 overexpression	Bladder Cancer Bladder Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	pembrolizumab + LY3500518 Resistant: C3 – Early Trials	pembrolizumab + LY3500518 Resistant: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Melanoma Melanoma	PD-L1 overexpression PD-L1 overexpression	Melanoma Melanoma	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Head and Neck Cancer Head and Neck Cancer	PD-L1 overexpression PD-L1 overexpression	Head and Neck Cancer Head and Neck Cancer	nivolumab Sensitive: C3 – Early Trials	nivolumab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	M7824 Sensitive: C3 – Early Trials	M7824 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Melanoma Melanoma	PD-L1 overexpression PD-L1 overexpression	Melanoma Melanoma	ipilimumab Sensitive: C3 – Early Trials	ipilimumab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Melanoma Melanoma	PD-L1 overexpression PD-L1 overexpression	Melanoma Melanoma	nivolumab Sensitive: C3 – Early Trials	nivolumab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Ovarian Cancer Ovarian Cancer	PD-L1 overexpression PD-L1 overexpression	Ovarian Cancer Ovarian Cancer	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	olaparib Resistant: C3 – Early Trials	olaparib Resistant: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab + CP-675206 Sensitive: C3 – Early Trials	durvalumab + CP-675206 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Oral Cancer Oral Cancer	PD-L1 overexpression PD-L1 overexpression	Oral Cancer Oral Cancer	nivolumab + MGCD516 Sensitive: C3 – Early Trials	nivolumab + MGCD516 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	EGFR inhibitor Resistant: C3 – Early Trials	EGFR inhibitor Resistant: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Sensitive: C3 – Early Trials	PD-L1 inhibitor Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	ipilimumab + cemiplimab Sensitive: C3 – Early Trials	ipilimumab + cemiplimab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	PD-L1 overexpression PD-L1 overexpression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	AB122 Sensitive: C3 – Early Trials	AB122 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma	PD-L1 overexpression PD-L1 overexpression	Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma	AB122 Sensitive: C3 – Early Trials	AB122 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	PD-L1 overexpression PD-L1 overexpression	Diffuse Large B Cell Lymphoma Diffuse Large B Cell Lymphoma	R-CHOP Resistant: C3 – Early Trials	R-CHOP Resistant: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	PD-L1 overexpression PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab + afatinib Sensitive: C3 – Early Trials	pembrolizumab + afatinib Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	AB122 + AB154 + AB928 Sensitive: C3 – Early Trials	AB122 + AB154 + AB928 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	AB122 + AB154 Sensitive: C3 – Early Trials	AB122 + AB154 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	PD-L1 overexpression PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	PD-L1 overexpression PD-L1 overexpression	Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: C3 – Early Trials	nivolumab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Gastric Cancer Gastric Cancer	PD-L1 overexpression PD-L1 overexpression	Gastric Cancer Gastric Cancer	SHR-1701 Sensitive: C3 – Early Trials	SHR-1701 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	SHR-1701 Sensitive: C3 – Early Trials	SHR-1701 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	anlotinib + AK104 Sensitive: C3 – Early Trials	anlotinib + AK104 Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	toripalimab Sensitive: C3 – Early Trials	toripalimab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 overexpression PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials	PD-L1 inhibitor Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Cervical Cancer Cervical Cancer	PD-L1 overexpression PD-L1 overexpression	Cervical Cancer Cervical Cancer	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	PD-L1 overexpression PD-L1 overexpression	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	durvalumab Sensitive: C3 – Early Trials	durvalumab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	PD-L1 overexpression PD-L1 overexpression	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	durvalumab Sensitive: C3 – Early Trials	durvalumab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	PD-L1 overexpression PD-L1 overexpression	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	sintilimab Sensitive: C3 – Early Trials	sintilimab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	PD-L1 overexpression PD-L1 overexpression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	sintilimab Sensitive: C3 – Early Trials	sintilimab Sensitive: C3 – Early Trials
PD-L1 overexpression PD-L1 overexpression	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	PD-L1 overexpression PD-L1 overexpression	Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma	nivolumab Sensitive: C4 – Case Studies	nivolumab Sensitive: C4 – Case Studies